Chemical pollutant linked to risk of cancer in males
the ONA take:
According to new findings published in the journal Science of the Total Environment, researchers from the University of Granada in Granada, Spain, have found that exposure to a chemical pollutant known as PCB-153 is positively linked to the risk of cancer in males. This agent can still be found in some fat-rich foods, particularly large, fat-rich fish.
For the study, researchers analyzed the accumulated levels of various pollutants in the body fat of 268 adults and identified those who developed cancer over a 9-year period.
Results showed that the accumulated exposure of PCB-153 was positively associated with the risk of cancer among men.
PCB-153 is part of a group of chemicals widely used in various types of industrial equipment. Because of its high resistance to degradation, the researchers suggest that fat food is the main source of exposure to the chemical pollutant. A fat-rich diet may be the cause of high PCB levels.
The researchers also hypothesize that the pollutant could interact with hormone receptors, produce free radicals, or alter DNA, thus causing cancer.
Exposure to a chemical pollutant known as PCB-153 is positively linked to the risk of cancer in males.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|